Blood tests and surveys may predict cancer treatment success

NCT ID NCT04776837

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could predict how well the treatment worked at the first scan. The goal was to find better ways to track disease progression and response without relying solely on imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict how well a cancer treatment is working early on, using simple blood tests and patient surveys.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any immediate changes in care, and the results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.